QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
It is well established that carriers of pathogenic BRCA mutations are at an increased risk in women for breast, ovarian, pancreatic cancer and melanoma, and in men, prostate, pancreatic, male breast cancer, and melanoma. To this group of cancers, a…
Prostate cancer is a major public health problem causing considerable side effects, suffering, death, and healthcare costs. The early treatment of clinically localized disease decreases prostate cancer deaths, but over-treatment of all early-stage patients results in unnecessary adverse side effects…
More of the prostate cancer deaths occurred in men initially diagnosed with Gleason 6 (low-grade) than in those diagnosed with Gleason 7 (high-grade). Prostate cancer is sometimes portrayed as a “toothless tiger,” and it is said that “Every man will…
2023 National Comprehensive Cancer Center Network Guidelines Dr. Catalona is a member of the National Comprehensive Cancer Center Network (NCCN) Early Prostate Cancer Detection Guideline Panel. In a recent article on which Dr. Catalona is a co- author, the…
Local therapies using stereotactic ablative radiation (SABR) are increasingly being used to treat patients with oligometastatic disease (only a few metastases) due to the accumulating evidence regarding its efficacy in improving oncologic outcomes. In patients with prostate cancer, there is…
In a widely publicized study in the lay media from the United Kingdom in which 15-year outcomes were reported in patients with screening- detected prostate cancer who were randomly assigned to receive (1) active monitoring with PSA measurements (not true active…
A study including several members of PCASP (Prostate Cancer Active Surveillance Project) on which Dr. Catalona is a co-author reported on the variation in the use of active surveillance for low-risk prostate cancer in the U.S. They evaluated 20,809 patients…
Induced pluripotent stem cell project with Cedars Sinai Dr. Catalona is collaborating with Dan Theodorescu, MD Ph.D. (a cancer center director and a cancer researcher) and Clive Svendsen, Ph.D. (a neuroscientist with expertise in induced pluripotent stem cell technology) at…
Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population- based screening is unknown. This study invited 37,887 men who were 50-60 years of age to undergo regular PSA screening. Participants with…
Each year, the American Cancer Society estimates the number of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. In 2023, 1,958,310 new cancer cases and 609,820 cancer…
"*" indicates required fields
